Antibodies that bind to human programmed death ligand 1 (PD-L1)
US9709568B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2013 |
| Grant date | Jul 18, 2017 |
| Priority date | — |
| Expiry date | Dec 18, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70532
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present disclosure provides isolated antibodies that specifically bind to human PD-L1, as well as antigen binding fragments of such antibodies, and kits comprising the anti-PD-L1 antibodies or binding fragments and a set of reagents for detecting a complex of the antibody, or antigen binding fragment thereof, bound to human PD-L1. The antibodies and antigen binding fragments of this disclosure are useful for immunohistochemical detection of human PD-L1 expression in tissue samples. Nucleic acid molecules encoding the antibodies and antigen binding fragments of this disclosure, as well as expression vectors and host cells for expression thereof, are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.